The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Well that's annoying ... and I have lost quite a bit. Commiserations all round. But it does confirm my doubts about endless posts saying it was going to take-off on Friday or this time next week it would be £10 or £30 and so on. Should have realised that once vaccines came along that did change things, and then the results were too late and too bad. A shame, but more for the scientists involved that investors - they have worked their fingers to bone to try and achieve results. Let's hope something can be salvaged from their brilliant research.
Yes I agree that mid-Jan seems most likely and it looks promising. However (and at risk of being slammed again!), there are notes of caution out there. Personally, I am holding and believe that SYN will a a great help in the battle against Covid and other lung diseases, but it is wise - for me - to be aware of other voices, eg https://www.clinicaltrialsarena.com/analysis/timing-of-synairgen-phase-iii-nebulised-covid-19-treatment-remains-a-challenge/
This is not trying to be negative, just adding to the knowledge we are sharing ... the bottom line is no-one knows anything until the results are in - obviously.
Blimey, talk about sensitive. I have been an investor since these shares were 55p and have continued to hold and sometimes buy when I could afford to. Pointing out that other drugs exists is not downplaying anything it is simply pointing out what is going on elsewhere. Having dipped in here occasionally over many many months what I am struck bu is a) if anyone suggests anything other than optimism they get slammed b) the price is always going up by tomorrow/next week, next month.Like Del Boy, this time next year we are all going to be millionaires. Let's hope so - I certainly intend to wait and expect good news, but to ask people to go elsewhere because they happen to mention other interesting drugs in the pipeline makes a mockery of a place which is intended to exchange info which MAY have an impact on the share price. I am not SUPPORTING these other drugs, just saying they exist.
There are a number of other anti-virals about to get the go-ahead as well, which may or may not impact on Synairgen, depending how they work in the real world ... See this from recent news article about France:
President Macron said in his speech to the nation in October: “Because France, very early on, focused on research into treatments, and we have ordered a lot of them well in advance, we will benefit from a new weapon to fight the virus with the arrival, from the end of the year, of the first truly effective treatments against serious forms of Covid.”
The European Commission, has now given marketing authorisation for Regkirona, a monoclonal antibody medicine created by South Korean laboratory Celltrion, and the similar Ronapreve, by Swiss firm Roche.
They were found in trials to significantly reduce chances of a vulnerable patient being hospitalised or dying. Ronapreve had been given a temporary authorisation in France for immunosuppressed people, from August this year to January.
Other promising treatments are being developed around the world, including Molnupiravir, an antiviral from the US for those who are moderately ill, which reduces the risk of serious forms. The European Medicines Agency has recommended it be allowed in emergencies.
France has ordered doses of molnupiravir and several other treatments, such as XAV-19, by Nantes laboratory Xenothera (30,000 doses), which is the French project that is most advanced. XAV-19 is for patients with moderate Covid, to avoid aggravation of their symptoms and transfer to intensive care.
The lab is seeking authorisation for early access from the French authorities and told The Connexion it has 20,000 doses ready for sale when this comes, which it hopes will be at the start of 2022 at the latest.
Must say I agree with your post and not sure why people get so aggressive when someone suggests we will not all be millionaires next week. Syn is a good product but there are similar, possibly more effective, drugs being developed in several countries. It would be shortsighted not to acknowledge this. Syn may be ahead in some respects (ie further along in trials) but not in other ways. We just have to wait to see what happens with their trials and other companies' developments, surely, rather than diss posters. And what does Loool mean?!
I agree with Tattyhead2! I have been following these posts for a while now and have got used to the 'this time next week/month/year we are going to be millionaires'. The amount of times this share has been tipped to go north in just a few days... I believe it could do well, and bought in at 50p up to £1.50 and intend to hold. But it seems fairly clear that it will not move until results are in and even then may not be quite as spectacular as we all hope. There are other similar drugs in development along with other new therapeutics, many of which look promising. And of course the vaccines are highly effective as well, even though they won't reach everyone for a long time.
And by the way, I don't think there is any Govt conspiracy to do down this drug, they are simply waiting like everyone else for the results to come in. Boris himself benefited from Synairgen, it is said, so is hardly likely to have a vendetta. Bottom line: this is a promising drug in a competitive field which may do well if the results come back positive. This is why it is the price it is and not £3-30 (the range that has been mentioned here over the last few months!) Happy to be proved wrong and by Friday (it is usually a Friday) it will have shot up ...
You are right, they are months (at least) behind, but there are several competitive drugs being developed, some of which seem to be very much more effective and these are not fly-by-night companies (if that is what you mean by mom n pop). Some are coming out of established/establishment labs. Synairgen is ahead and effective and I agree should be able to capitalise on their lead, but there are other interferon treatments in the works which will, in my view, impact on its SP at some point. But of course I could easily be wrong about that ...
Other labs are developing something similar which may influence SP? https://www.globenewswire.com/news-release/2020/10/27/2115020/0/en/BetterLife-CEO-Highlights-Crucial-Difference-Between-the-Company-s-Interferon-Alpha-2b-and-Other-Treatements.html
As I understand it, several US labs are developing something similar. The news is good, in that they are sure interferon is effective, though they feel their version is MORE effective (obvs) but are way behind in terms of trial/approvals etc. But of course it is mostly about who gets there first, and everyone seems to agree that Synairgen are in the lead.